Biogen Idec Inc (BIIB) 340.87 $BIIB
Exciting News: A Game-Changing Alzheimer's Drug Could be on Its Way
Todd Campbell, The Motley Fool - Motley Fool - Sat Dec 06, 9:43AM CST
Source: Flickr user Garry Knight. According to a 2011 study, only cancer worried Americans more than being diagnosed with Alzheimer's disease, and for 22% of people responding, the risk of getting Alzheimer's disease was their No. 1 health...
BIIB: 340.87 (-0.31)
Walgreens (WAG) Up on 4.9% Y/Y Rise in November Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 3:45PM CST
Following the news release, Walgreens' (WAG) shares rose 1.7% to eventually close at $67.90 yesterday.
BIIB: 340.87 (-0.31), ANIP: 53.29 (-0.16), WAG: 68.60 (+0.70), AFFX: 9.26 (+0.12)
Celldex's Glembatumumab Vedotin in Phase II for Melanoma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 2:10PM CST
Celldex Therapeutics, Inc. (CLDX) commenced an open-label phase II study on glembatumumab vedotin for unresectable stage III or IV melanoma.
BIIB: 340.87 (-0.31), ANIP: 53.29 (-0.16), CLDX: 18.27 (+0.01), AMAG: 41.18 (+0.59)
What Biogen Idec's Alzheimer's Candidate Could Be Worth
Cory Renauer - Seeking Alpha - Fri Dec 05, 2:02PM CST
When Biogen Idec (NASDAQ: BIIB ) initiated a Phase 1b trial with potential Alzheimer's disease (AD) therapy BIIB37, management laid out success criteria that would support a decision to aggressively invest in accelerating the program. More...
BIIB: 340.87 (-0.31)
Incyte's Jakafi Gets FDA Approval for Polycythemia Vera - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 12:00PM CST
Incyte's (INCY) Jakafi gained FDA approval for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.
BIIB: 340.87 (-0.31), INCY: 75.20 (+1.08), LLY: 71.85 (-0.53), NVS: 95.83 (+0.06)
Cramer Says It May Finally Be Time to Buy Laggard Gilead Sciences
at The Street - Fri Dec 05, 11:18AM CST
TheStreet's Jim Cramer says Gilead Sciences may finally start to catch up to its peers, based on a research report from J.P. Morgan.
BIIB: 340.87 (-0.31), GILD: 104.59 (+2.77), ABBV: 69.71 (+0.14), REGN: 423.23 (+0.02), CELG: 114.13 (+0.50)
Bayer Files Hemophilia A Drug Marketing Application in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 9:20AM CST
The HealthCare segment at Bayer (BAYRY) announced that the company has submitted Marketing Authorization Application in Europe for BAY 81-8973.
BIIB: 340.87 (-0.31), AMGN: 169.24 (+2.69), AMAG: 41.18 (+0.59)
Array BioPharma, Inc. (ARRY) in Focus: Stock Soars 14.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 8:18AM CST
Array BioPharma, Inc. (ARRY) was a big mover last session, as the company saw its shares rise by over 14% on the day.
BIIB: 340.87 (-0.31), ANIP: 53.29 (-0.16), AFFX: 9.26 (+0.12), ARRY: 4.93 (+0.46)
'Mad Money' Lightning Round: Buy, Buy, Buy Texas Instruments
at The Street - Fri Dec 05, 5:00AM CST
Cramer wants you to avoid Plug Power and Peabody Energy but would buy Molson Coors and Constellation Brands.
BIIB: 340.87 (-0.31), GPRO: 72.18 (+0.20), DRE: 19.39 (-0.01), ALU: 3.47 (unch), PLUG: 3.60 (-0.10), TAP: 74.92 (+1.66), STZ: 95.09 (+0.91), HPQ: 39.55 (+0.48), VTR: 71.06 (-1.50), GTLS: 37.22 (-0.02), CELG: 114.13 (+0.50), BTU: 8.89 (+0.01), GILD: 104.59 (+2.77), TXN: 55.58 (+0.17), REGN: 423.23 (+0.02), HTA: 12.91 (-0.05)
Cramer's Lightning Round - Constellation Brands Has Real Magic (12/4/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Fri Dec 05, 3:36AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday December 4. Bullish Calls: Constellation Brands (NYSE: STZ ): "That is my favorite. It has Corona and Modelo. It has real magic." ...
GPRO: 72.18 (+0.20), BIIB: 340.87 (-0.31), DRE: 19.39 (-0.01), PLUG: 3.60 (-0.10), ALU: 3.47 (unch), TAP: 74.92 (+1.66), STZ: 95.09 (+0.91), HPQ: 39.55 (+0.48), GTLS: 37.22 (-0.02), VTR: 71.06 (-1.50), CELG: 114.13 (+0.50), BTU: 8.89 (+0.01), GILD: 104.59 (+2.77), TXN: 55.58 (+0.17), CSCO: 27.50 (-0.27), REGN: 423.23 (+0.02), HTA: 12.91 (-0.05)
Jim Cramer's 'Mad Money' Recap: Google Is Better Than the Market Thinks
at The Street - Thu Dec 04, 7:31PM CST
After a lackluster year, Cramer expects Google to deliver solid results come January when it reports earnings.
KMI: 41.12 (-0.34), RH: 85.18 (+2.20), BIIB: 340.87 (-0.31), GD: 145.15 (+0.27), GE: 26.01 (-0.08), CAG: 36.99 (+0.48), STKL: 11.48 (-0.22), VTR: 71.06 (-1.50), TWX: 84.26 (-0.40), SBUX: 83.57 (+2.26), YHOO: 50.99 (+0.58), T: 33.94 (+0.03), IDT: 17.87 (+0.34), COST: 143.25 (+0.23), DG: 68.21 (+0.42), GOOGL: 528.08 (-14.50), TRAK: 47.55 (-2.24), REGN: 423.23 (+0.02), HTA: 12.91 (-0.05), AMZN: 312.63 (-4.30), GPRO: 72.18 (+0.20), HD: 99.64 (+0.69), DRE: 19.39 (-0.01), PLUG: 3.60 (-0.10), ALU: 3.47 (unch), FB: 76.36 (+1.12), SLXP: 105.62 (-0.26), TAP: 74.92 (+1.66), STZ: 95.09 (+0.91), HABT: 34.21 (+0.72), FCAU: 13.61 (+0.39), BMY: 60.65 (+1.76), HPQ: 39.55 (+0.48), GTLS: 37.22 (-0.02), CELG: 114.13 (+0.50), UA: 69.43 (-0.16), BTU: 8.89 (+0.01), LB: 82.92 (+0.25), ESV: 31.07 (-0.39), GILD: 104.59 (+2.77), VALE: 8.38 (+0.03), TXN: 55.58 (+0.17), MRO: 29.23 (-0.61), BAS: 6.10 (-0.59), CVX: 110.87 (-1.41), BABA: 107.90 (-1.27)
Amgen's Blincyto Gets FDA Nod, Carries Boxed Warning - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 5:45PM CST
Amgen's (AMGN) Blincyto gained FDA approval for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
BIIB: 340.87 (-0.31), ANIP: 53.29 (-0.16), ILMN: 189.90 (-0.93), AMGN: 169.24 (+2.69)
ADMA Biologics' RI-002 Positive in Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 5:30PM CST
ADMA Biologics' (ADMA) RI-002 met the primary endpoint in a late-stage study conducted in patients suffering from primary immune deficiency disease.
BIIB: 340.87 (-0.31), ADMA: 10.40 (-0.40), ANIP: 53.29 (-0.16), AMGN: 169.24 (+2.69)
Hot Drugmakers Build More Labs, Grab Space In Boston
at Investor's Business Daily - Thu Dec 04, 3:47PM CST
The greater Boston area has seen an influx of some fast-growing biotechs like Biogen Idec (BIIB) that have been taking lab space, a trend that's driven down vacancy rates in a big way. That's under way while the the biotech sector is surging -- IBD's...
BIIB: 340.87 (-0.31), ARE: 88.13 (+0.01), GILD: 104.59 (+2.77), BAX: 74.22 (+0.65), PFE: 31.99 (+0.32), AMGN: 169.24 (+2.69), AGIO: 106.02 (+1.97)
Gilead Sciences: An Alpha Stock Through The Good And Bad Times
Michael Grogan - at Seeking Alpha - Thu Dec 04, 2:14PM CST
AGN: 213.35 (-0.36), BIIB: 340.87 (-0.31), GILD: 104.59 (+2.77), AMGN: 169.24 (+2.69), NVS: 95.83 (+0.06)
Synageva Completes BLA Submission for Sebelipase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 2:10PM CST
Synageva BioPharma Corp. (GEVA) announced the completion of the rolling submission of a biologics license application to the FDA for sebelipase alfa for LAL deficiency.
CYTK: 4.66 (+0.10), BIIB: 340.87 (-0.31), GEVA: 84.78 (+3.01), AMGN: 169.24 (+2.69)
Array BioPharma Regains Binimetinib Rights from Novartis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 2:00PM CST
Shares of Array BioPharma Inc. (ARRY) shot up in after-market hours trading after the company announced reaching a definitive agreement with Novartis (NVS) to regain full worldwide rights to oncology candidate binimetinib, an MEK inhibitor.
BIIB: 340.87 (-0.31), GSK: 46.04 (+0.15), ARRY: 4.93 (+0.46), NVS: 95.83 (+0.06)
Will New Alzheimer's Drug Boost Biogen?
at Investor's Business Daily - Thu Dec 04, 11:32AM CST
Today we'll check in on Biogen Idec (BIIB), which develops treatments for multiple sclerosis, cancer and autoimmune diseases. It's also been working on a drug to slow Alzheimer's, called BIIB-037. Earlier this week, Biogen said it's moving that drug...
BIIB: 340.87 (-0.31)
Stock Market Today: Stocks Worsen Near Midday; Airlines Rally
at Investor's Business Daily - Thu Dec 04, 10:52AM CST
Stocks took a turn for the worse near Thursday's midday, as the Nasdaq erased gains. The S&P 500 and the Dow Jones industrial average lost 0.5% each. Both wiped out all of Wednesday's gains and then some. The Nasdaq fell 0.3% after giving up a 0.2%...
BIIB: 340.87 (-0.31), RYAAY: 68.04 (-0.04), ALK: 57.26 (+0.52), BITA: 74.57 (-3.64), UAL: 63.03 (+1.28)
The Zacks Analyst Blog Highlights: Biogen Idec, Eli Lilly, AstraZeneca and Amgen
PR Newswire - Thu Dec 04, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Biogen Idec Inc. (Nasdaq:BIIB-Free Report), Eli Lilly (NYSE:LLY-Free Report), AstraZeneca (NYSE:AZN-Free Report) and Amgen Inc. (Nasdaq:AMGN-Free Report).
BIIB: 340.87 (-0.31), AMGN: 169.24 (+2.69), LLY: 71.85 (-0.53)
Exciting News: A Game-Changing Alzheimer's Drug Could be on Its Way
Todd Campbell, The Motley Fool - Motley Fool - Sat Dec 06, 9:43AM CST
Source: Flickr user Garry Knight. According to a 2011 study, only cancer worried Americans more than being diagnosed with Alzheimer's disease, and for 22% of people responding, the risk of getting Alzheimer's disease was their No. 1 health...
BIIB: 340.87 (-0.31)
Walgreens (WAG) Up on 4.9% Y/Y Rise in November Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 3:45PM CST
Following the news release, Walgreens' (WAG) shares rose 1.7% to eventually close at $67.90 yesterday.
BIIB: 340.87 (-0.31), ANIP: 53.29 (-0.16), WAG: 68.60 (+0.70), AFFX: 9.26 (+0.12)
Celldex's Glembatumumab Vedotin in Phase II for Melanoma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 2:10PM CST
Celldex Therapeutics, Inc. (CLDX) commenced an open-label phase II study on glembatumumab vedotin for unresectable stage III or IV melanoma.
BIIB: 340.87 (-0.31), ANIP: 53.29 (-0.16), CLDX: 18.27 (+0.01), AMAG: 41.18 (+0.59)
What Biogen Idec's Alzheimer's Candidate Could Be Worth
Cory Renauer - Seeking Alpha - Fri Dec 05, 2:02PM CST
When Biogen Idec (NASDAQ: BIIB ) initiated a Phase 1b trial with potential Alzheimer's disease (AD) therapy BIIB37, management laid out success criteria that would support a decision to aggressively invest in accelerating the program. More...
BIIB: 340.87 (-0.31)
Incyte's Jakafi Gets FDA Approval for Polycythemia Vera - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 12:00PM CST
Incyte's (INCY) Jakafi gained FDA approval for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.
BIIB: 340.87 (-0.31), INCY: 75.20 (+1.08), LLY: 71.85 (-0.53), NVS: 95.83 (+0.06)
Cramer Says It May Finally Be Time to Buy Laggard Gilead Sciences
at The Street - Fri Dec 05, 11:18AM CST
TheStreet's Jim Cramer says Gilead Sciences may finally start to catch up to its peers, based on a research report from J.P. Morgan.
BIIB: 340.87 (-0.31), GILD: 104.59 (+2.77), ABBV: 69.71 (+0.14), REGN: 423.23 (+0.02), CELG: 114.13 (+0.50)
Bayer Files Hemophilia A Drug Marketing Application in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 9:20AM CST
The HealthCare segment at Bayer (BAYRY) announced that the company has submitted Marketing Authorization Application in Europe for BAY 81-8973.
BIIB: 340.87 (-0.31), AMGN: 169.24 (+2.69), AMAG: 41.18 (+0.59)
Array BioPharma, Inc. (ARRY) in Focus: Stock Soars 14.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 8:18AM CST
Array BioPharma, Inc. (ARRY) was a big mover last session, as the company saw its shares rise by over 14% on the day.
BIIB: 340.87 (-0.31), ANIP: 53.29 (-0.16), AFFX: 9.26 (+0.12), ARRY: 4.93 (+0.46)
'Mad Money' Lightning Round: Buy, Buy, Buy Texas Instruments
at The Street - Fri Dec 05, 5:00AM CST
Cramer wants you to avoid Plug Power and Peabody Energy but would buy Molson Coors and Constellation Brands.
BIIB: 340.87 (-0.31), GPRO: 72.18 (+0.20), DRE: 19.39 (-0.01), ALU: 3.47 (unch), PLUG: 3.60 (-0.10), TAP: 74.92 (+1.66), STZ: 95.09 (+0.91), HPQ: 39.55 (+0.48), VTR: 71.06 (-1.50), GTLS: 37.22 (-0.02), CELG: 114.13 (+0.50), BTU: 8.89 (+0.01), GILD: 104.59 (+2.77), TXN: 55.58 (+0.17), REGN: 423.23 (+0.02), HTA: 12.91 (-0.05)
Cramer's Lightning Round - Constellation Brands Has Real Magic (12/4/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Fri Dec 05, 3:36AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday December 4. Bullish Calls: Constellation Brands (NYSE: STZ ): "That is my favorite. It has Corona and Modelo. It has real magic." ...
GPRO: 72.18 (+0.20), BIIB: 340.87 (-0.31), DRE: 19.39 (-0.01), PLUG: 3.60 (-0.10), ALU: 3.47 (unch), TAP: 74.92 (+1.66), STZ: 95.09 (+0.91), HPQ: 39.55 (+0.48), GTLS: 37.22 (-0.02), VTR: 71.06 (-1.50), CELG: 114.13 (+0.50), BTU: 8.89 (+0.01), GILD: 104.59 (+2.77), TXN: 55.58 (+0.17), CSCO: 27.50 (-0.27), REGN: 423.23 (+0.02), HTA: 12.91 (-0.05)
Jim Cramer's 'Mad Money' Recap: Google Is Better Than the Market Thinks
at The Street - Thu Dec 04, 7:31PM CST
After a lackluster year, Cramer expects Google to deliver solid results come January when it reports earnings.
KMI: 41.12 (-0.34), RH: 85.18 (+2.20), BIIB: 340.87 (-0.31), GD: 145.15 (+0.27), GE: 26.01 (-0.08), CAG: 36.99 (+0.48), STKL: 11.48 (-0.22), VTR: 71.06 (-1.50), TWX: 84.26 (-0.40), SBUX: 83.57 (+2.26), YHOO: 50.99 (+0.58), T: 33.94 (+0.03), IDT: 17.87 (+0.34), COST: 143.25 (+0.23), DG: 68.21 (+0.42), GOOGL: 528.08 (-14.50), TRAK: 47.55 (-2.24), REGN: 423.23 (+0.02), HTA: 12.91 (-0.05), AMZN: 312.63 (-4.30), GPRO: 72.18 (+0.20), HD: 99.64 (+0.69), DRE: 19.39 (-0.01), PLUG: 3.60 (-0.10), ALU: 3.47 (unch), FB: 76.36 (+1.12), SLXP: 105.62 (-0.26), TAP: 74.92 (+1.66), STZ: 95.09 (+0.91), HABT: 34.21 (+0.72), FCAU: 13.61 (+0.39), BMY: 60.65 (+1.76), HPQ: 39.55 (+0.48), GTLS: 37.22 (-0.02), CELG: 114.13 (+0.50), UA: 69.43 (-0.16), BTU: 8.89 (+0.01), LB: 82.92 (+0.25), ESV: 31.07 (-0.39), GILD: 104.59 (+2.77), VALE: 8.38 (+0.03), TXN: 55.58 (+0.17), MRO: 29.23 (-0.61), BAS: 6.10 (-0.59), CVX: 110.87 (-1.41), BABA: 107.90 (-1.27)
Amgen's Blincyto Gets FDA Nod, Carries Boxed Warning - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 5:45PM CST
Amgen's (AMGN) Blincyto gained FDA approval for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
BIIB: 340.87 (-0.31), ANIP: 53.29 (-0.16), ILMN: 189.90 (-0.93), AMGN: 169.24 (+2.69)
ADMA Biologics' RI-002 Positive in Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 5:30PM CST
ADMA Biologics' (ADMA) RI-002 met the primary endpoint in a late-stage study conducted in patients suffering from primary immune deficiency disease.
BIIB: 340.87 (-0.31), ADMA: 10.40 (-0.40), ANIP: 53.29 (-0.16), AMGN: 169.24 (+2.69)
Hot Drugmakers Build More Labs, Grab Space In Boston
at Investor's Business Daily - Thu Dec 04, 3:47PM CST
The greater Boston area has seen an influx of some fast-growing biotechs like Biogen Idec (BIIB) that have been taking lab space, a trend that's driven down vacancy rates in a big way. That's under way while the the biotech sector is surging -- IBD's...
BIIB: 340.87 (-0.31), ARE: 88.13 (+0.01), GILD: 104.59 (+2.77), BAX: 74.22 (+0.65), PFE: 31.99 (+0.32), AMGN: 169.24 (+2.69), AGIO: 106.02 (+1.97)
Gilead Sciences: An Alpha Stock Through The Good And Bad Times
Michael Grogan - at Seeking Alpha - Thu Dec 04, 2:14PM CST
AGN: 213.35 (-0.36), BIIB: 340.87 (-0.31), GILD: 104.59 (+2.77), AMGN: 169.24 (+2.69), NVS: 95.83 (+0.06)
Synageva Completes BLA Submission for Sebelipase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 2:10PM CST
Synageva BioPharma Corp. (GEVA) announced the completion of the rolling submission of a biologics license application to the FDA for sebelipase alfa for LAL deficiency.
CYTK: 4.66 (+0.10), BIIB: 340.87 (-0.31), GEVA: 84.78 (+3.01), AMGN: 169.24 (+2.69)
Array BioPharma Regains Binimetinib Rights from Novartis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 2:00PM CST
Shares of Array BioPharma Inc. (ARRY) shot up in after-market hours trading after the company announced reaching a definitive agreement with Novartis (NVS) to regain full worldwide rights to oncology candidate binimetinib, an MEK inhibitor.
BIIB: 340.87 (-0.31), GSK: 46.04 (+0.15), ARRY: 4.93 (+0.46), NVS: 95.83 (+0.06)
Will New Alzheimer's Drug Boost Biogen?
at Investor's Business Daily - Thu Dec 04, 11:32AM CST
Today we'll check in on Biogen Idec (BIIB), which develops treatments for multiple sclerosis, cancer and autoimmune diseases. It's also been working on a drug to slow Alzheimer's, called BIIB-037. Earlier this week, Biogen said it's moving that drug...
BIIB: 340.87 (-0.31)
Stock Market Today: Stocks Worsen Near Midday; Airlines Rally
at Investor's Business Daily - Thu Dec 04, 10:52AM CST
Stocks took a turn for the worse near Thursday's midday, as the Nasdaq erased gains. The S&P 500 and the Dow Jones industrial average lost 0.5% each. Both wiped out all of Wednesday's gains and then some. The Nasdaq fell 0.3% after giving up a 0.2%...
BIIB: 340.87 (-0.31), RYAAY: 68.04 (-0.04), ALK: 57.26 (+0.52), BITA: 74.57 (-3.64), UAL: 63.03 (+1.28)
The Zacks Analyst Blog Highlights: Biogen Idec, Eli Lilly, AstraZeneca and Amgen
PR Newswire - Thu Dec 04, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Biogen Idec Inc. (Nasdaq:BIIB-Free Report), Eli Lilly (NYSE:LLY-Free Report), AstraZeneca (NYSE:AZN-Free Report) and Amgen Inc. (Nasdaq:AMGN-Free Report).
BIIB: 340.87 (-0.31), AMGN: 169.24 (+2.69), LLY: 71.85 (-0.53)
